Q-omics provides the consensus-scored NPHP1 profile across patient tissues and cancer cell-line models. NPHP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NPHP1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, NPHP1 RNA expression shows 19,650 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where NPHP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPHP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPHP1 survival associations across molecular data types. NPHP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPHP1 RNA expression–survival associations across cancer types. High NPHP1 expression shows unfavorable associations in LGG, KICH and HNSC, but favorable associations in BRCA, LUAD and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for NPHP1 RNA expression.
This table summarizes NPHP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NPHP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPHP1 shows lower tumor expression in KICH, LUSC, BLCA, LUAD and THCA and higher tumor expression in LIHC. The KICH box plot shows higher NPHP1 RNA expression in normal versus tumor tissue (log2 FC = −1.691, t-test p < 0.001).
This table shows molecular features associated with NPHP1 in patient tissues and cancer cell lines. In patient samples, NPHP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPHP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
